Beta Bionics, Inc. (BBNX) presents a deeply negative liquidation recovery posture as of March 31, 2026. Total assets of $304.4M are dominated by financial instruments—$30.2M cash/equivalents, $169.3M short-term investments, and $39.9M long-term investments—that carry high recovery rates under the liquidation lens. However, the non-financial asset base is thin and largely non-recoverable: PP&E net book value of $10.2M recovers at perhaps 50-70% (~$5-7M), inventory of $23.7M recovers at 60% (~$14.2M), and operating lease ROU assets of $6.2M are typically zero-recovery on liquidation. Total liabilities of $33.2M are carried at face value, including $6.9M operating lease liability (full undiscounted commitment of $8.3M doesn't extinguish on wind-up), $17.3M accrued liabilities and other current liabilities, and $1.7M current deferred revenue (obligation to deliver performance, not cash). Applying standard liquidation haircuts: recoverable assets approximate $30.2M (cash, 100%) + ~$208.7M (investments at ~99.8% given minimal unrealized loss of $0.1M net) + ~$15.1M (AR at 95% on $15.9M gross, net of $0.16M allowance) + ~$14.2M (inventory at 60%) + ~$6.1M (PP&E at 60%) + ~$0.6M (prepaid/other tangible at partial recovery) = approximately $275M in recoverable asset value against $33.2M in liabilities at face, yielding estimated equity recovery of roughly $240-245M on a ~$271M book equity. The MFFAIS-reported OLV of $41.4M and LLV of $17.7M reflect a much tighter view that presumably applies steeper haircuts or excludes investment securities from the liquid pool—practitioners should note the investment portfolio represents $209M in AFS debt securities (predominantly U.S. Treasuries per MD&A), which is the decisive driver of recovery and should be treated near-par. The primary liquidation risk is operational burn rate: Q1 2026 operating cash outflow was $23.8M, net loss was $21.9M, and adjusted EBITDA was negative $17.7M. The company has a going-concern runway stated as through first half of 2028 on current balance. No long-term debt exists; the liability stack is entirely short-cycle operating obligations. An active FDA Warning Letter and Form 483 quality system remediation (costs appearing as add-backs in adjusted EBITDA at $562K in Q4 2025 and Q1 2026) represent a contingent liability not separately quantified on the balance sheet—filing discusses this in MD&A but does not separately tag a reserve or contingent liability in XBRL. The prior filing was the 10-K for the year ended December 31, 2025. The investment portfolio is materially unchanged in character but has declined modestly as operating cash outflows consumed a portion of IPO proceeds deployed in early 2025.
▼ Community Notes